Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
View in:
PubMed
subject areas
Adenocarcinoma
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Humans
Rectal Neoplasms
Vascular Endothelial Growth Factor A
authors with profiles
Kenneth S. Cohen